Upstaza Unia Europejska - polski - EMA (European Medicines Agency)

upstaza

ptc therapeutics international limited - eladocagene exuparvovec - metabolizm aminokwasowy, wrodzone błędy - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

BiResp Spiromax Unia Europejska - polski - EMA (European Medicines Agency)

biresp spiromax

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - preparaty do obturacyjne choroby dróg oddechowych, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

DuoResp Spiromax Unia Europejska - polski - EMA (European Medicines Agency)

duoresp spiromax

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - preparaty do obturacyjne choroby dróg oddechowych, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

Trimbow Unia Europejska - polski - EMA (European Medicines Agency)

trimbow

chiesi farmaceutici s.p.a. - beclometasone beklometazonu, formoterola fumaran dihydrat, glycopyrronium bromek - choroba płuc, przewlekła obturacyjna - preparaty do obturacyjne choroby dróg oddechowych, - maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. copdmaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5. asthmamaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

Cernevit - Proszek do sporządzania roztworu do wstrzykiwań i infuzji Polska - polski - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

cernevit - proszek do sporządzania roztworu do wstrzykiwań i infuzji

baxter polska sp. z o.o. - retynolu palmitynian + cholekalcyferol + dl-alfa-tokoferol + kwas askorbowy + kokarboksylaza czterowodna + sól sodowa fosforanu ryboflawiny + pirydoksyny chlorowodorek + cyjanokobalamina + kwas foliowy + dekspantenol + biotyna + nikotynamid - proszek do sporządzania roztworu do wstrzykiwań i infuzji - -

MBE 150 mg + 7,29 mg + 200 mg Kapsułki miękkie Polska - polski - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

mbe 150 mg + 7,29 mg + 200 mg kapsułki miękkie

przedsiębiorstwo produkcji farmaceutycznej hasco-lek s.a. - magnesii oxidum + pyridoxini hydrochloridum (vitaminum b6) + int-rac-alfa-tocopherylis acetas - kapsułki miękkie - 150 mg + 7,29 mg + 200 mg